Published in Blood on March 19, 2007
F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood (2009) 3.02
Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia (2008) 2.29
The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo. Am J Hematol (2009) 2.12
Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth. Blood (2008) 2.06
Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. J Clin Invest (2008) 1.81
The pathogenesis of the bone disease of multiple myeloma. Bone (2008) 1.51
Treatment of newly diagnosed myeloma. Leukemia (2008) 1.27
Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling. Blood (2009) 1.25
Role of decorin in the antimyeloma effects of osteoblasts. Blood (2008) 1.19
Engineered nanomedicine for myeloma and bone microenvironment targeting. Proc Natl Acad Sci U S A (2014) 1.16
Diagnosis and treatment of bone disease in multiple myeloma: spotlight on spinal involvement. Scientifica (Cairo) (2013) 1.15
Advances in the understanding of myeloma bone disease and tumour growth. Br J Haematol (2010) 1.13
Withaferin A: a proteasomal inhibitor promotes healing after injury and exerts anabolic effect on osteoporotic bone. Cell Death Dis (2013) 1.09
The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects. Leukemia (2012) 1.07
A proteasome inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by downregulating metastatic genes. Clin Cancer Res (2010) 1.07
Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo. Am J Hematol (2009) 1.05
The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors. J Natl Compr Canc Netw (2009) 1.03
Impaired osteoblastogenesis in a murine model of dominant osteogenesis imperfecta: a new target for osteogenesis imperfecta pharmacological therapy. Stem Cells (2012) 1.00
Tumor-host cell interactions in the bone disease of myeloma. Bone (2010) 0.96
A novel bioluminescent mouse model and effective therapy for adult T-cell leukemia/lymphoma. Cancer Res (2007) 0.95
Targeting the bone microenvironment in multiple myeloma. J Bone Miner Metab (2010) 0.94
A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients. Haematologica (2010) 0.94
E3 ubiquitin ligase-mediated regulation of bone formation and tumorigenesis. Cell Death Dis (2013) 0.94
Osteoblastogenesis and tumor growth in myeloma. Leuk Lymphoma (2010) 0.93
Effect of the HDAC inhibitor vorinostat on the osteogenic differentiation of mesenchymal stem cells in vitro and bone formation in vivo. Acta Pharmacol Sin (2013) 0.91
First-line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro. Eur J Haematol (2010) 0.89
Myeloma bone disease: Pathophysiology and management. J Bone Oncol (2013) 0.87
Bone metastasis: the importance of the neighbourhood. Nat Rev Cancer (2016) 0.86
Preclinical studies of novel targeted therapies. Hematol Oncol Clin North Am (2007) 0.86
Proteasome inhibitors and bone disease. Semin Hematol (2012) 0.86
New therapies in multiple myeloma. Clin Exp Med (2007) 0.86
Characterization of the molecular mechanism of the bone-anabolic activity of carfilzomib in multiple myeloma. PLoS One (2013) 0.86
Extracellular matrix degradation and tissue remodeling in periprosthetic loosening and osteolysis: focus on matrix metalloproteinases, their endogenous tissue inhibitors, and the proteasome. Biomed Res Int (2013) 0.85
Bone building with bortezomib. J Clin Invest (2008) 0.84
Proteasome inhibition and its therapeutic potential in multiple myeloma. Biologics (2010) 0.84
Bisphosphonates as antimyeloma drugs. Leukemia (2011) 0.83
Recognizing and treating secondary osteoporosis. Nat Rev Rheumatol (2012) 0.82
Role of bone-anabolic agents in the treatment of breast cancer bone metastases. Breast Cancer Res (2014) 0.82
Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics. World J Stem Cells (2014) 0.81
Bone anabolic agents for the treatment of multiple myeloma. Cancer Microenviron (2011) 0.81
Multiple myeloma and bone disease: pathogenesis and current therapeutic approaches. Hippokratia (2010) 0.80
Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling. Biomed Res Int (2015) 0.80
Soluble molecules and bone metabolism in multiple myeloma: a review. Clin Cases Miner Bone Metab (2008) 0.77
Relationship between abnormal osteoblasts and cellular immunity in multiple myeloma. Cancer Cell Int (2014) 0.77
In vitro migratory aberrancies of mesenchymal stem cells derived from multiple myeloma patients only partially modulated by bortezomib. Int J Clin Exp Pathol (2014) 0.77
Effects of proteasome inhibitors on bone cancer. Bonekey Rep (2013) 0.77
Mechanism of action of immunomodulatory agents in multiple myeloma. Med Oncol (2010) 0.76
Changes in osteoblastic activity in patient who received bortezomib as second line treatment for plasma cell myeloma: a prospective multicenter study. Biomed Res Int (2014) 0.76
Adipose, Bone, and Myeloma: Contributions from the Microenvironment. Calcif Tissue Int (2016) 0.75
Multiple myeloma in the marrow: pathogenesis and treatments. Ann N Y Acad Sci (2016) 0.75
E11/Podoplanin Protein Stabilization Through Inhibition of the Proteasome Promotes Osteocyte Differentiation in Murine in Vitro Models. J Cell Physiol (2015) 0.75
Genetic factors influencing the risk of multiple myeloma bone disease. Leukemia (2015) 0.75
(18)F-fluoride-PET for dynamic in vivo monitoring of bone formation in multiple myeloma. EJNMMI Res (2016) 0.75
Bone formation following lenalidomide-dexamethasone combination therapy in cases of multiple myeloma refractory to high-dose chemotherapy with bortezomib and autologous peripheral blood stem cell transplantation: report of a case and review of the literature. Int J Clin Exp Pathol (2015) 0.75
The effects of proteasome inhibitors on bone remodeling in multiple myeloma. Bone (2016) 0.75
Targeting bone as a therapy for myeloma. Cancer Microenviron (2011) 0.75
Lenalidomide restores the osteogenic differentiation of bone marrow mesenchymal stem cells from multiple myeloma patients via deactivating Notch signaling pathway. Oncotarget (2017) 0.75
Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol (2005) 3.81
Survival of elderly patients with acute myeloid leukemia. Haematologica (2004) 2.99
Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells. Blood (2008) 2.94
Continuous positive airway pressure treatment of sleepy patients with milder obstructive sleep apnea: results of the CPAP Apnea Trial North American Program (CATNAP) randomized clinical trial. Am J Respir Crit Care Med (2012) 2.35
A novel and effective strategy for the isolation of adipose-derived stem cells: minimally manipulated adipose-derived stem cells for more rapid and safe stem cell therapy. Plast Reconstr Surg (2014) 2.27
Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition. Blood (2006) 1.77
Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. J Clin Oncol (2002) 1.76
Diabetes impairs hematopoietic stem cell mobilization by altering niche function. Sci Transl Med (2011) 1.75
Mesenchymal cells recruit and regulate T regulatory cells. Exp Hematol (2008) 1.72
Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood (2002) 1.68
Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood (2005) 1.59
Polybrominated diphenyl ether (PBDE) flame retardants: environmental contamination, human body burden and potential adverse health effects. Acta Biomed (2008) 1.54
Characterization of mitochondrial and extra-mitochondrial oxygen consuming reactions in human hematopoietic stem cells. Novel evidence of the occurrence of NAD(P)H oxidase activity. J Biol Chem (2005) 1.50
Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia. Leuk Res (2011) 1.50
Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Blood (2002) 1.47
Long-term follow-up of syndromic craniosynostosis after Le Fort III halo distraction: a cephalometric and CT evaluation. J Plast Reconstr Aesthet Surg (2012) 1.41
A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol. Blood (2005) 1.39
IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. Blood (2005) 1.35
Bone-marrow derived hematopoietic stem/progenitor cells express multiple isoforms of NADPH oxidase and produce constitutively reactive oxygen species. Biochem Biophys Res Commun (2006) 1.30
Evaluation of sham-CPAP as a placebo in CPAP intervention studies. Sleep (2010) 1.29
Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment. Cancer Res (2007) 1.18
Pancreatic carcinoma recurrence in the remnant pancreas after a pancreaticoduodenectomy. JOP (2006) 1.17
Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways. Blood (2008) 1.16
Endothelial cells in the bone marrow of patients with multiple myeloma. Blood (2003) 1.15
Imaging of a small bowel cavernous hemangioma: report of a case with emphasis on the use of computed tomography and enteroclysis. Acta Biomed (2007) 1.13
HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma. Cancer (2003) 1.10
In human endothelial cells rapamycin causes mTORC2 inhibition and impairs cell viability and function. Cardiovasc Res (2008) 1.07
Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer: the role of anthracycline dose intensity. Am J Clin Oncol (2006) 1.07
Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone disease. Exp Hematol (2009) 1.06
Angiogenesis and multiple myeloma. Cancer Microenviron (2011) 1.05
Clinicopathologic features of 2 new cases of uterine tumors resembling ovarian sex cord tumors. Int J Gynecol Pathol (2010) 1.04
CXCR3 and its binding chemokines in myeloma cells: expression of isoforms and potential relationships with myeloma cell proliferation and survival. Haematologica (2006) 1.03
One dose of a porcine circovirus 2 subunit vaccine induces humoral and cell-mediated immunity and protects against porcine circovirus-associated disease under field conditions. Vet Microbiol (2010) 1.03
Transconjunctival approach in orbital traumatology: a review of 56 cases. J Craniomaxillofac Surg (2010) 1.03
New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL). Exp Hematol (2004) 1.01
Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines. Biochem Pharmacol (2009) 1.01
The p53 family protein p73 provides new insights into cancer chemosensitivity and targeting. Clin Cancer Res (2009) 1.01
CC-chemokine ligand 20/macrophage inflammatory protein-3α and CC-chemokine receptor 6 are overexpressed in myeloma microenvironment related to osteolytic bone lesions. Cancer Res (2008) 0.99
MEK1 inhibition sensitizes primary acute myelogenous leukemia to arsenic trioxide-induced apoptosis. Blood (2006) 0.99
Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis. Blood (2003) 0.99
OPG/RANKL system imbalance in a case of hepatitis C-associated osteosclerosis: the pathogenetic key? Clin Rheumatol (2004) 0.97
Melphalan versus melphalan plus busulphan in conditioning to autologous stem cell transplantation for low-risk multiple myeloma. Hematol J (2004) 0.96
Impact of XIAP protein levels on the survival of myeloma cells. Haematologica (2008) 0.96
A novel gene signature for molecular diagnosis of human prostate cancer by RT-qPCR. PLoS One (2008) 0.94
Myeloma cells and bone marrow osteoblast interactions: role in the development of osteolytic lesions in multiple myeloma. Leuk Lymphoma (2007) 0.94
Construction and evaluation of a disposable pH sensor based on a large core plastic optical fiber. Rev Sci Instrum (2011) 0.93
Leukocyte-specific phosphoprotein-1 and PU.1: two useful markers for distinguishing T-cell-rich B-cell lymphoma from lymphocyte-predominant Hodgkin's disease. Haematologica (2004) 0.92
The hypoxia-inducible factor is stabilized in circulating hematopoietic stem cells under normoxic conditions. FEBS Lett (2007) 0.92
Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules. Exp Hematol (2012) 0.92
Primary nodal marginal zone B-cell lymphoma: clinical features and prognostic assessment of a rare disease. Br J Haematol (2007) 0.91
Tolerance induction by megadose hematopoietic progenitor cells: expansion of veto cells by short-term culture of purified human CD34(+) cells. Blood (2002) 0.90
Pioglitazone improves in vitro viability and function of endothelial progenitor cells from individuals with impaired glucose tolerance. PLoS One (2012) 0.90
Tuberculosis in kindergarten and primary school, Italy, 2008-2009. Emerg Infect Dis (2011) 0.89
Osteogenic differentiation of mesenchymal stem cells in multiple myeloma: identification of potential therapeutic targets. Exp Hematol (2009) 0.88
Cellular targeting of engineered heterologous antigens is a determinant factor for bovine herpesvirus 4-based vaccine vector development. Clin Vaccine Immunol (2009) 0.88
Flat epithelial atypia and atypical ductal hyperplasia: carcinoma underestimation rate. Breast J (2009) 0.88
MDR1 polymorphism influences the outcome of multiple myeloma patients. Br J Haematol (2007) 0.87
Immune regulatory activity of CD34+ progenitor cells: evidence for a deletion-based mechanism mediated by TNF-alpha. Blood (2004) 0.87
Angiogenic switch in multiple myeloma. Hematology (2005) 0.87
Gastric metastasis from breast carcinoma. Report of three cases, diagnostic-therapeutic critical close examination and literature review. Ann Ital Chir (2010) 0.86
P53, bcl-2 and Ki-67 expression in adenoid cystic carcinoma of the palate. A clinico-pathologic study of 21 cases with long-term follow-up. Pathol Res Pract (2005) 0.86
Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study. Drugs Aging (2013) 0.86
The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. Haematologica (2010) 0.85
Effect of the macrolide antibacterial drug, tylosin, on TNBS-induced colitis in the rat. Pharmacology (2005) 0.85
Transplants across human leukocyte antigen barriers. Semin Hematol (2002) 0.85
Endothelial differentiation of hematopoietic stem and progenitor cells from patients with multiple myeloma. Clin Cancer Res (2008) 0.85